Jan 28 (Reuters) - U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on Wednesday, to develop and commercialize ...

Weight-loss drugs draw thousands of lawsuits alleging serious harm Economist warns coming financial crisis will make 2008 look like 'Sunday school picnic' Elon Musk says Tesla ending Models S and X ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing company Seamless Therapeutics. This morning’s deal with Seamless centers on ...

The new Apple Creator Studio bundles the company's flagship creative software in a monthly subscription package for the first time. It's a great value, assuming you haven't bought most of them ...